ZLAB
Zai Lab Ltd

1,224
Mkt Cap
$2.22B
Volume
2.03M
52W High
$44.34
52W Low
$19.51
PE Ratio
-10.22
ZLAB Fundamentals
Price
$19.93
Prev Close
$20.02
Open
$20.02
50D MA
$27.88
Beta
1.23
Avg. Volume
709,179.57
EPS (Annual)
-$2.60
P/B
2.90
Rev/Employee
$213,583.80
Loading...
Loading...
News
all
press releases
Zai Lab (NASDAQ:ZLAB) Issues Earnings Results
Zai Lab (NASDAQ:ZLAB - Get Free Report) announced its earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by...
MarketBeat·18d ago
News Placeholder
More News
News Placeholder
Zai Lab (NASDAQ:ZLAB) Sets New 52-Week Low on Disappointing Earnings
Zai Lab (NASDAQ:ZLAB) Hits New 52-Week Low Following Weak Earnings...
MarketBeat·18d ago
News Placeholder
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Companys senior management team will participate in the following investor conferences in November and December 2025...
Business Wire·25d ago
News Placeholder
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating...
Business Wire·1mo ago
News Placeholder
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...
PR Newswire·1mo ago
News Placeholder
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of...
Business Wire·1mo ago
News Placeholder
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug...
Business Wire·1mo ago
News Placeholder
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug
The company holds co-development and commercialization rights for Bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.
Stocktwits·3mo ago
News Placeholder
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·4mo ago
News Placeholder
Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·4mo ago

Latest ZLAB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.